Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma

Ozaki, Shuji; Handa, Hiroshi; Saitoh, Takayuki; Murakami, Hirokazu; Itagaki, Mitsuhiro; Asaoku, Hideki; Suzuki, Kenshi; Isoda, Atsushi; Matsumoto, Morio; Sawamura, Morio; Sunami, Kazutaka; Takezako, Naoki; Hagiwara, Shotaro; Kuroda, Yuko; Chou, Takaaki; Nagura, Eiichi; Shimizu, Kazuyuki

doi:10.1007/s00277-019-03702-1

Cited by 13 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, a revised version of the ISS disease stage has been proposed and validated in further studies. 8,[15][16][17][18][19][20][21][22][23] This revised staging system was presented as simple and powerful because it allows three different prognostic groups to be identified based on three other known prognostic factors: ISS, high-risk CA and LDH level higher than normal. 8 We could not deny the simplification, since from 3 factors, only one has been constructed, and the results of our study had effectively shown an improved prediction for ISS stages I and III by adding the presence of high-risk CA or high LDH level.…”

Section: Discussionmentioning

confidence: 99%

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Schavgoulidze¹,

Lauwers‐Cancès²,

Perrot³

et al. 2022

haematol

View full text Add to dashboard Cite

In the era of personalized treatment in multiple myeloma, high-risk patients must be accurately defined. The International Myeloma Working Group recommends using the Revised International Staging System (R-ISS) to identify high-risk patients. The main purpose of our work was to explore the heterogeneity of outcome among R-ISS stage II patients assessing the impact of ISS, chromosomal abnormalities (CA) and LDH level in this subgroup. Data were issued from 1,343 newly diagnosed myeloma patients up to 65 years, enrolled in 3 clinical trials implemented by the Intergroupe Francophone du Myelome. All patients were eligible to an intensive treatment. Patients R-ISS stage II but ISS stage I had 1.6 times more risk of death than patients R-ISS stage I (adjusted HR 1.6; 95% CI, 1.1 to 2.2; P = .01) and patients R-ISS stage II but ISS stage III had a better overall survival than patients R-ISS stage III (adjusted HR 0.7; 95% CI, 0.4 to 0.9, P = .02). However, among patients classified in R-ISS II, ISS stage and CA (del(17p) and t(4;14)) were still relevant prognostic factors for death. Dividing R-ISS stage II into 3 subgroups: ISS I with standard risk CA, ISS II or III with standard risk CA and, high risk CA patients, median overall survivals were respectively not reached, 112 and 71 months (P < 0.001). In conclusion, stratification of patients in the R-ISS stage II group can be improved by taking into account CA and ISS. However, this does not improve predictive performance of survival models.

show abstract

Section: Discussionmentioning

confidence: 99%

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Schavgoulidze¹,

Lauwers‐Cancès²,

Perrot³

et al. 2022

haematol

View full text Add to dashboard Cite

show abstract

“…ISS and RISS stages reflect the disease burden of MM [ 27 , 28 ]. Soekojo et al [ 29 ] reported that when compared with the RISS, there was a high level of concordance in high-risk patients identified using FISH analysis with an independent cohort of 375 patients.…”

Section: Discussionmentioning

confidence: 99%

Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma

et al. 2021

View full text Add to dashboard Cite

Background Whole-body diffusion-weighted imaging (WB-DWI) is a method for evaluating bone marrow infiltration in multiple myeloma (MM). This study seeks to elucidate the correlation between the apparent diffusion coefficient (ADC) value and some selected clinical parameters. Methods A total of 101 Chinese patients with MM who had undergone WB-DWI from May 2017 to May 2019 were enrolled in this study. The ADC values of the MM lesions and the clinical parameters were quantified at the first (baseline) visit and after four-course induction chemotherapy. Multiple linear regression and logistic analyses were carried out to find the implicit inherent relationships within the patients’ data. Results The paired Wilcoxon test showed that the ADC values at the baseline visit (ADC0) were significantly lower than the values after four-course induction chemotherapy (ADC4 c) (p < 0.001), including different therapeutic responses. The Revised International Staging System (RISS) stage, type of MM, and β2-microglobulin (β2-MG) were predictors of clinically significant increases or decreases in the ADC values (p < 0.05). Multiple linear regression showed that the ADC0 was negatively associated with β2-MG (p < 0.001) and immunoglobulin heavy chain gene rearrangement (p = 0.012), while the RISS Stage III (p = 0.001), type IgG λ (p = 0.005), and albumin were negatively associated with ADC4 c (p = 0.010). The impacts of the therapeutic response were associated with ADC0 and immunoglobulin heavy chain gene rearrangement (p < 0.001). Conclusion The ADC values of WB-DWI may be associated with clinical parameters of MM including the fluorescence in situ hybridization result, and may be useful in the prognosis of patients with MM. Trial Registration: ChiCTR2000029587

show abstract

“…ISS and RISS stages re ect the disease burden of MM. [21,22] Moreover, the RISS staging system can predict the prognosis of patients with MM. [23] Beksac et al [24] found that patients with ISS stage I had a signi cantly better prognosis than stage and patients.…”

Section: Discussionmentioning

confidence: 99%

Correlations Between Apparent Diffusion Coefficient Values of WB-DWI and Clinical Parameters in Multiple Myeloma

Zhang

Bian

Zhao

et al. 2020

Preprint

View full text Add to dashboard Cite

PURPOSE: Whole-body diffusion-weighted imaging (WB-DWI) is a method for evaluating bone marrow infiltration in multiple myeloma (MM). This study seeks to elucidate the correlation between the apparent diffusion coefficient (ADC) value and some selected clinical parameters. MATERIALS AND METHODS: 101 Chinese patients with MM who had undergone WB-DWI from May 2017 to May 2019 were enrolled in this study. The ADC values of the MM lesions and the clinical parameters were quantified at the first (baseline) visit and after four-course induction chemotherapy. Multiple linear regression and logistic analyses were carried out to find the implicit inherent relationships within the patients’ data.RESULTS: The paired Wilcoxon test showed that the ADC values at the baseline visit (ADC0) were significantly lower than the values after four-course induction chemotherapy (ADC4 c) (p < 0.001), including different therapeutic responses. The Revised International Staging System (RISS) stage, type of MM, and β2-microglobulin (β2-MG) were predictors of clinically significant increases or decreases in the ADC values (p< 0.05). Multiple linear regression showed that the ADC0 was negatively associated with β2-MG (p ＜ 0.001) and immunoglobulin heavy chain gene rearrangement (p = 0.012), while the RISS Stage Ⅲ (p = 0.001), type IgG λ (p = 0.005), and albumin were negatively associated with ADC4 c (p = 0.010). The impacts of the therapeutic response were associated with ADC0 and immunoglobulin heavy chain gene rearrangement (p ＜ 0.001).CONCLUSION: The ADC values of WB-DWI may be associated with clinical parameters of MM including the fluorescence in situ hybridization (FISH) result, and may be useful in the prognosis of patients with MM.TRIAL REGISTRATION: ChiCTR2000029587

show abstract

Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma

Cited by 13 publications

References 26 publications

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma

Correlations Between Apparent Diffusion Coefficient Values of WB-DWI and Clinical Parameters in Multiple Myeloma

Contact Info

Product

Resources

About

Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma

Cited by 13 publications

References 26 publications

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma

Correlations Between Apparent Diffusion Coefficient Values of WB-DWI&nbsp;and Clinical Parameters in Multiple Myeloma

Contact Info

Product

Resources

About

Correlations Between Apparent Diffusion Coefficient Values of WB-DWI and Clinical Parameters in Multiple Myeloma